These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22096987)

  • 1. [Immunobiological properties of Yersinia pestis antigens].
    Byvalov AA; Ovodov IuS
    Bioorg Khim; 2011; 37(4):452-63. PubMed ID: 22096987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protecting against plague: towards a next-generation vaccine.
    Williamson ED; Oyston PC
    Clin Exp Immunol; 2013 Apr; 172(1):1-8. PubMed ID: 23480179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
    Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
    Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.
    Eisele NA; Anderson DM
    Clin Vaccine Immunol; 2009 Dec; 16(12):1720-7. PubMed ID: 19828767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plague vaccines and the molecular basis of immunity against Yersinia pestis.
    Quenee LE; Schneewind O
    Hum Vaccin; 2009 Dec; 5(12):817-23. PubMed ID: 19786842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The F1 and V subunit vaccine protects against plague in the absence of IL-4 driven immune responses.
    Elvin SJ; Williamson ED
    Microb Pathog; 2000 Oct; 29(4):223-30. PubMed ID: 10993741
    [No Abstract]   [Full Text] [Related]  

  • 9. Prospects for new plague vaccines.
    Feodorova VA; Corbel MJ
    Expert Rev Vaccines; 2009 Dec; 8(12):1721-38. PubMed ID: 19943765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
    Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
    FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis.
    Friedlander AM; Welkos SL; Worsham PL; Andrews GP; Heath DG; Anderson GW; Pitt ML; Estep J; Davis K
    Clin Infect Dis; 1995 Oct; 21 Suppl 2():S178-81. PubMed ID: 8845449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The weak interaction of LcrV and TLR2 does not contribute to the virulence of Yersinia pestis.
    Reithmeier-Rost D; Hill J; Elvin SJ; Williamson D; Dittmann S; Schmid A; Wilharm G; Sing A
    Microbes Infect; 2007 Jul; 9(8):997-1002. PubMed ID: 17556003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague.
    Leary SE; Griffin KF; Galyov EE; Hewer J; Williamson ED; Holmström A; Forsberg A; Titball RW
    Microb Pathog; 1999 Mar; 26(3):159-69. PubMed ID: 10089156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague.
    Elvin SJ; Williamson ED
    Microb Pathog; 2004 Oct; 37(4):177-84. PubMed ID: 15458778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the role of LcrV-Toll-like receptor 2-mediated immunomodulation in the virulence of Yersinia pestis.
    Pouliot K; Pan N; Wang S; Lu S; Lien E; Goguen JD
    Infect Immun; 2007 Jul; 75(7):3571-80. PubMed ID: 17438030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.
    Sanapala S; Rahav H; Patel H; Sun W; Curtiss R
    Vaccine; 2016 May; 34(21):2410-2416. PubMed ID: 27060051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel CTL epitopes identified through a Y. pestis proteome-wide analysis in the search for vaccine candidates against plague.
    Zvi A; Rotem S; Zauberman A; Elia U; Aftalion M; Bar-Haim E; Mamroud E; Cohen O
    Vaccine; 2017 Oct; 35(44):5995-6006. PubMed ID: 28606812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FPR1 is the plague receptor on host immune cells.
    Osei-Owusu P; Charlton TM; Kim HK; Missiakas D; Schneewind O
    Nature; 2019 Oct; 574(7776):57-62. PubMed ID: 31534221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
    Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
    Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of monoclonal antibody to V antigen from Yersinia pestis.
    Sato K; Nakajima R; Hara F; Une T; Osada Y
    Contrib Microbiol Immunol; 1991; 12():225-9. PubMed ID: 1935094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.